Pharmacological properties of JDTic: a novel κ-opioid receptor antagonist

Abstract Biological studies were conducted on (3 R )-7-Hydroxy- N -{(1 S )-1-{[(3 R ,4 R )-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl}-1,2,3,4-tetrahydro-3-isoquinoline-carboxamide (JDTic), the first potent κ-selective opioid receptor antagonist not derived from an opiate class of compounds. In the mouse tail-flick test, JDTic, administered subcutaneously (s.c.), blocked anticociceptive activity for up to 2 weeks. When JDTic was administered either s.c. or p.o. 24 h before the selective KOP (κ)-opioid receptor agonist, enadoline, AD 50s of 4.1 and 27.3, respectively, were obtained. A time-course study of JDTic versus enadoline indicated significant antagonist p.o. activity up to 28 days. In contrast, JDTic, s.c., failed to antagonize the analgesic effects of the selective MOP (μ)-opioid receptor agonist, sufentanil. In the squirrel monkey shock titration antinociception test, JDTic given intramuscularly (i.m.) shifted the trans -3,4-dichloro- N -methyl- N -(2-[1-pyrrolidinyl] cyclohexyl) benzeneacetamide (U50,488) dose–effect curve to the right. In the U50,488-induced diuresis rat test, JDTic, s.c., suppressed diuretic activity with a greater potency than that of nor-binaltorphimine (nor-BNI). Thus, JDTic is a potent long- and orally acting selective κ-opioid antagonist.

[1]  C. Chavkin,et al.  Dynorphin is a specific endogenous ligand of the kappa opioid receptor. , 1982, Science.

[2]  A. Lipkowski,et al.  Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists. , 1987, Life sciences.

[3]  A. Levine,et al.  The kappa-opioid antagonist GNTI reduces U50,488-, DAMGO-, and deprivation-induced feeding, but not butorphanol- and neuropeptide Y-induced feeding in rats , 2001, Brain Research.

[4]  M. Aceto,et al.  Etorphines: mu-opioid receptor-selective antinociception and low physical dependence capacity. , 1997, European journal of pharmacology.

[5]  L. Harris,et al.  ANTINOCICEPTIVE ACTIVITY OF THE NARCOTIC ANTAGONIST ANALGESICS AND ANTAGONISTIC ACTIVTY OF NARCOTIC ANALGESICS IN RODENTS , 1971 .

[6]  J. Rhodes,et al.  Naloxone treatment for irritable bowel syndrome — a randomized controlled trial with an oral formulation , 2002, Alimentary pharmacology & therapeutics.

[7]  J. Billings,et al.  Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation. , 2002, Journal of pain and symptom management.

[8]  J. Leander.  A kappa opioid effect: increased urination in the rat. , 1983, The Journal of pharmacology and experimental therapeutics.

[9]  E. Butelman,et al.  Pharmacotherapy of addictions , 2002, Nature Reviews Drug Discovery.

[10]  L. Harris,et al.  The effect of various neurohumoral modulators on the activity of morphine and the narcotic antagonists in the tail-flick and phenylquinone tests. , 1970, The Journal of pharmacology and experimental therapeutics.

[11]  A. Lipkowski,et al.  Bimorphinans as highly selective, potent kappa opioid receptor antagonists. , 1987, Journal of medicinal chemistry.

[12]  James B. Thomas,et al.  Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist. , 2003, Journal of medicinal chemistry.

[13]  F I Carroll,et al.  Identification of the first trans-(3R,4R)- dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid kappa receptor antagonist activity. , 2001, Journal of medicinal chemistry.

[14]  S. Mascarella,et al.  Identification of an opioid kappa receptor subtype-selective N-substituent for (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine. , 1998, Journal of medicinal chemistry.

[15]  S. Lukas,et al.  Buprenorphine treatment of refractory depression. , 1995, Journal of clinical psychopharmacology.

[16]  Fred E. D'Amour,et al.  A METHOD FOR DETERMINING LOSS OF PAIN SENSATION , 1941 .

[17]  J. Leander.  Further study of kappa opioids on increased urination. , 1983, The Journal of pharmacology and experimental therapeutics.

[18]  C. Chavkin,et al.  κ Opioid Receptor Antagonism and Prodynorphin Gene Disruption Block Stress-Induced Behavioral Responses , 2003, The Journal of Neuroscience.

[19]  R. Vink,et al.  kappa-Opioid antagonist improves cellular bioenergetics and recovery after traumatic brain injury. , 1991, The American journal of physiology.

[20]  R. M. Jones,et al.  Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors. , 1998, Journal of medicinal chemistry.

[21]  D. Zimmerman,et al.  Selective opioid receptor agonists and antagonists: research tools and potential therapeutic agents. , 1990, Journal of medicinal chemistry.

[22]  T. Endoh,et al.  Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo. , 1992, Archives internationales de pharmacodynamie et de therapie.

[23]  R. M. Jones,et al.  Potent and selective indolomorphinan antagonists of the kappa-opioid receptor. , 2000, Journal of medicinal chemistry.

[24]  L. Dykstra.  Effects of buprenorphine on shock titration in squirrel monkeys. , 1985, The Journal of pharmacology and experimental therapeutics.

[25]  D. Wong,et al.  3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines: opioid antagonists with potent anorectant activity. , 1993, Journal of medicinal chemistry.

[26]  R. Tallarida,et al.  Manual of Pharmacologic Calculations: With Computer Programs , 1984 .

[27]  J. Gidda,et al.  Discovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonist for the treatment of gastrointestinal motility disorders. , 1994, Journal of medicinal chemistry.

[28]  J. Szmuszkovicz.  U-50,488 and the к receptor Part II: 1991–1998 , 1999 .

[29]  C. Lipinski.  Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[30]  Philip S. Portoghese,et al.  Antidepressant-Like Effects of κ-Opioid Receptor Antagonists in the Forced Swim Test in Rats , 2003, Journal of Pharmacology and Experimental Therapeutics.

[31]  L. Dykstra,et al.  Antagonism of the analgesic effects of mu and kappa opioid agonists in the squirrel monkey. , 1988, The Journal of pharmacology and experimental therapeutics.

[32]  N. Mello,et al.  Kappa opioid antagonist effects of the novel kappa antagonist 5′-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys , 2002, Psychopharmacology.

[33]  P. Portoghese,et al.  Narcotic antagonistic potency of bivalent ligands which contain .beta.-naltrexamine. Evidence for simultaneous occupation of proximal recognition sites , 1982 .

[34]  John A. Nelder,et al.  Statistics In Biology. , 1971 .

[35]  H. Yamamura,et al.  Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test. , 1992, The Journal of pharmacology and experimental therapeutics.

[36]  P. Portoghese,et al.  Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. , 1988, The Journal of pharmacology and experimental therapeutics.

[37]  P. Portoghese,et al.  5'-Guanidinonaltrindole, a highly selective and potent κ-opioid receptor antagonist , 2000 .

[38]  B. H. Hill,et al.  An open-label study of a functional opioid κ antagonist in the treatment of opioid dependence , 2000 .

[39]  S. Mascarella,et al.  Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonists. , 1998, Journal of medicinal chemistry.

[40]  S. Husbands,et al.  The role of the side chain in determining relative delta- and kappa-affinity in C5'-substituted analogues of naltrindole. , 2003, Journal of medicinal chemistry.